1. The effect of chemotherapy regimens in male germ cell tumors on the development of primary hypogonadism
- Author
-
Analena Handke, Marla Geller-von Bargen, Aykhan Isgandarov, Mulham al Nader, Ulrich Krafft, Christopher Darr, Boris Hadaschik, Viktor Grünwald, and Lukas Püllen
- Subjects
Germ cell tumor ,Secondary hypogonadism ,Medicine ,Science - Abstract
Abstract Male germ cell tumors (GCT) have excellent survival. Long-term sequelae in cancer survivors are an evolving field. We evaluated the risk of patients with GCT to develop primary hypogonadism and adherence to guideline-recommended therapy in a real-world cohort. Monocentric study at a tertiary cancer centre to evaluate treated GCT-patients (2001–2019). Post therapeutic male endocrine function, International Index of Erectile Function (IIEF)-5 and The aging males’ symptoms rating scale (AMS) questionnaires were assessed. The overall response rates were low, with 44 of 402 contacted patients participating in the study. From these, 32(73%) underwent blood analysis, 42(95%) answered the IIEF-5 and 43(98%) the AMS. Latent hypogonadism (serum testosterone 8–12 nmol/l) was found in n = 9 (28%) and manifest hypogonadism (testosterone 50%, which underscored the clinical need to evaluate endocrine function in cancer survivors. We further indicated the difficulties of today’s research and provided starting points to assess barriers for study participations.
- Published
- 2024
- Full Text
- View/download PDF